Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | peroxisome proliferator-activated receptor delta | Starlite/ChEMBL | References |
Homo sapiens | peroxisome proliferator-activated receptor alpha | Starlite/ChEMBL | References |
Homo sapiens | peroxisome proliferator-activated receptor gamma | Starlite/ChEMBL | References |
Canis lupus familiaris | Peroxisome proliferator-activated receptor alpha | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Schistosoma mansoni | nuclear hormone receptor superfamily protein-related | Get druggable targets OG5_137778 | All targets in OG5_137778 |
Schistosoma japonicum | IPR008946,Nuclear receptor, ligand-binding,domain-containing | Get druggable targets OG5_137778 | All targets in OG5_137778 |
Schistosoma japonicum | ko:K08701 nuclear receptor, subfamily 1, invertebrate, putative | Get druggable targets OG5_137778 | All targets in OG5_137778 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0282 | 0.2858 | 0.3598 |
Loa Loa (eye worm) | carboxylesterase | 0.0282 | 0.2858 | 0.3598 |
Echinococcus multilocularis | metabotropic glutamate receptor 5 | 0.0164 | 0.1391 | 0.0907 |
Brugia malayi | Metabotropic glutamate receptor precursor. | 0.0133 | 0.1007 | 0.3151 |
Brugia malayi | Carboxylesterase family protein | 0.0282 | 0.2858 | 1 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0282 | 0.2858 | 0.2744 |
Echinococcus multilocularis | small conductance calcium activated potassium | 0.069 | 0.7942 | 1 |
Schistosoma mansoni | metabotropic glutamate receptor 2 3 (mglur group 2) | 0.0152 | 0.1235 | 0.1096 |
Loa Loa (eye worm) | hypothetical protein | 0.0287 | 0.2928 | 0.3687 |
Loa Loa (eye worm) | hypothetical protein | 0.069 | 0.7942 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0164 | 0.1391 | 0.1751 |
Echinococcus granulosus | metabotropic glutamate receptor 5 | 0.0164 | 0.1391 | 0.0907 |
Loa Loa (eye worm) | glutamate receptor | 0.0133 | 0.1007 | 0.1268 |
Loa Loa (eye worm) | hypothetical protein | 0.0258 | 0.2561 | 0.3224 |
Echinococcus granulosus | small conductance calcium activated potassium | 0.069 | 0.7942 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0282 | 0.2858 | 0.3598 |
Schistosoma mansoni | metabotropic glutamate receptor | 0.0112 | 0.0738 | 0.0591 |
Echinococcus multilocularis | carboxylesterase 5A | 0.0282 | 0.2858 | 0.2942 |
Echinococcus granulosus | acetylcholinesterase | 0.0282 | 0.2858 | 0.2942 |
Schistosoma mansoni | hypothetical protein | 0.069 | 0.7942 | 0.791 |
Schistosoma mansoni | calcium-activated potassium channel | 0.069 | 0.7942 | 0.791 |
Schistosoma mansoni | calcium-activated potassium channel | 0.0545 | 0.6142 | 0.6081 |
Brugia malayi | Carboxylesterase family protein | 0.0282 | 0.2858 | 1 |
Echinococcus granulosus | carboxylesterase 5A | 0.0282 | 0.2858 | 0.2942 |
Loa Loa (eye worm) | hypothetical protein | 0.0117 | 0.0799 | 0.1006 |
Echinococcus multilocularis | acetylcholinesterase | 0.0282 | 0.2858 | 0.2942 |
Echinococcus multilocularis | acetylcholinesterase | 0.0282 | 0.2858 | 0.2942 |
Brugia malayi | metabotropic glutamate receptor subtype 5a (mGluR5a), putative | 0.0121 | 0.0851 | 0.2573 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0282 | 0.2858 | 0.3598 |
Echinococcus granulosus | acetylcholinesterase | 0.0282 | 0.2858 | 0.2942 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | < 0.001 uM | Effective concentration against canine PPAR-alpha in Gal4 transactivation assay | ChEMBL. | 16107159 |
EC50 (functional) | < 0.001 uM | Effective concentration against canine PPAR-alpha in Gal4 transactivation assay | ChEMBL. | 16107159 |
EC50 (functional) | = 0.002 uM | Effective concentration against human PPAR-alpha in Gal4 transactivation assay | ChEMBL. | 16107159 |
EC50 (functional) | = 0.002 uM | Effective concentration against human PPAR-alpha in Gal4 transactivation assay | ChEMBL. | 16107159 |
EC50 (functional) | = 0.026 uM | Effective concentration against hamster PPAR-alpha in Gal4 transactivation assay | ChEMBL. | 16107159 |
EC50 (functional) | = 0.026 uM | Effective concentration against hamster PPAR-alpha in Gal4 transactivation assay | ChEMBL. | 16107159 |
EC50 (functional) | > 3 uM | Effective concentration against human PPAR-gamma in Gal4 transactivation assay; 28% response at 3 uM | ChEMBL. | 16107159 |
EC50 (functional) | > 3 uM | Effective concentration against human PPAR-gamma in Gal4 transactivation assay; 28% response at 3 uM | ChEMBL. | 16107159 |
IC50 (binding) | = 0.004 uM | In vitro binding affinity for PPAR-alpha | ChEMBL. | 16107159 |
IC50 (binding) | > 15 uM | In vitro binding affinity for PPAR-delta | ChEMBL. | 16107159 |
IC50 (binding) | > 15 uM | In vitro binding affinity for PPAR-gamma | ChEMBL. | 16107159 |
IC50 (binding) | > 15 uM | In vitro binding affinity for PPAR-delta | ChEMBL. | 16107159 |
IC50 (binding) | > 15 uM | In vitro binding affinity for PPAR-gamma | ChEMBL. | 16107159 |
TC (functional) | = -37 % | Effect of the compound at an oral dose of 0.3 mg/kg/day for 14 days on serum cholesterol level of hamster | ChEMBL. | 16107159 |
TC (functional) | = -33 % | Effect of the compound at an oral dose of 0.1 mg/kg/day for 14 days on serum cholesterol level of hamster | ChEMBL. | 16107159 |
TG (functional) | = -26 % | Effect of the compound at an oral dose of 0.3 mg/kg/day for 14 days on serum triglyceride level of hamster | ChEMBL. | 16107159 |
TG (functional) | = -13 % | Effect of the compound at an oral dose of 0.1 mg/kg/day for 14 days on serum triglyceride level of hamster | ChEMBL. | 16107159 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.